Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: An investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial

Diabetes Care

Volumn 39, Issue 2, 2016, Pages 206-213

  Idorn, Thomas ^a   Knop, Filip K ^a,b   Jørgensen, Morten B ^a   Jensen, Tonny ^a   Resuli, Marsela ^a   Hansen, Pernille M ^a   Christensen, Karl B ^a   Holst, Jens J ^b   Hornum, Mads ^a   Feldt Rasmussen, Bo ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Capital Region   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INULIN; LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADD ON THERAPY; ADULT; ARTICLE; BIOCHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DENMARK; DIALYSIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; WEIGHT REDUCTION; AGED; BODY WEIGHT; CHRONIC KIDNEY FAILURE; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

AGED; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY FAILURE, CHRONIC; LIRAGLUTIDE; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 84962110213     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1025     Document Type: Article

References (41)

1. U.S. Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013, 1.218.ii
2. Danish Society of Nephrology. Danish Ne-phrology Registry Annual Report 2013. Available from http://www.nephrology.dk/Publikationer/ Landsregister/%C3%85rsrapport%202013.pdf. Accessed 15 March 2015 [in Danish]
3. Duckworth WC, Bennett RG, Hamel FG. Insulin degradation: progress and potential. En-docr Rev 1998;19:608-624
4. Rocco MV, Berns JS; National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012;60:850-886
5. Williams ME, Garg R. Glycemic management in ESRD and earlier stages of CKD. Am J Kidney Dis 2014;63(Suppl. 2):S22-S38
6. Brouns R, De Deyn PP. Neurological complications in renal failure: a review. Clin Neurol Neurosurg 2004;107:1-16
7. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairmenton the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin (∗). Diabetes Obes Metab 2011;13:939-946
8. Arjona Ferreira JC, Corry D, Mogensen CE, et al. Efficacy and safety of sitagliptin in patients with type2diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis 2013;61:579-587
9. Boulton DW, Li L, Frevert EU, et al. Influence of renal or hepatic impairment on the pharma-cokinetics of saxagliptin. Clin Pharmacokinet 2011;50:253-265
10. Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab 2012;14:1032-1039
11. Nakata H, Sugitani S, Yamaji S, et al. Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease. Intern Med 2012;51:3045-3049
12. Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronickidney diseaseand type 2 diabetes. Clin Pharmacokinet 2015;54:1-21
13. European Medicines Agency. Annex I, summary of roduct characteristics (Victoza). Available from http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/ human/001026/WC500050017.pdf. Accessed 27 Februrary 2015
14. European Medicines Agency. Annex I, summary of product characteristics (Byetta). Available from http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/ human/000698/WC500051845.pdf. Accessed 26 January 2015
15. European Medicines Agency. Annex I, summary of product characteristics (Lyxumia). Available from http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product- Information/human/002445/WC500140401.pdf. Accessed 26 January 2015
16. European Medicines Agency. Annex I, summary of product characteristics (Eperzan). Available from http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/ human/002735/WC500165117.pdf. Accessed 26 January 2015
17. European Medicines Agency. Annex 1, summary of product characteristics (Bydureon). Available from http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product- Information/human/002020/WC500108241.pdf. Accessed 26 January 2015
18. European Medicines Agency. Annex I, summary of product characteristics (Trulicity). Available from http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/ human/002825/WC500179470.pdf. Accessed 26 January 2015
19. Idorn T, Knop FK, Jørgensen M, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study. BMJ Open 2013;3: e002764
20. Chatterjee DJ, Khutoryansky N, Zdravkovic M, Sprenger CR, Litwin JS. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. J Clin Pharmacol 2009;49:1353-1362
21. Morrow L, Hompesch M, Guthrie H, Chang D, Chatterjee DJ. Co-administration of liraglu-tide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacoki-netic interaction. Diabetes Obes Metab 2011; 13:75-80
22. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharma-codynamics, safetyand tolerability of NN2211,a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45:195-202
23. Christensen M, Knop FK, Vilsbøll T, Holst JJ. Lixisenatide for type 2 diabetes mellitus. Expert Opin Investig Drugs 2011;20:549-557
24. Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007;64:317-327
25. Liu Y-H, Ruus P. Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patients with renal impairment (Abstract). Diabetes 2009;59(Suppl. 1):A149-A150
26. FilippatosTD, Elisaf MS. Effects ofglucagon-like peptide-1 receptor agonists on renal function. World J Diabetes 2013;4:190-201
27. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003) 2009;49(Suppl. 1): S16-S29
28. Malm-Erjefält M, Bjørnsdottir I, Vanggaard J, et al. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopepti-dase. Drug Metab Dispos 2010;38:1944-1953
29. Davidson JA, Brett J, Falahati A, Scott D. Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract 2011;17:345-355
30. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue lir-aglutide. Br J Clin Pharmacol 2009;68:898-905
31. Osonoi T, Saito M, Tamasawa A, et al. Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study. PLoS One 2014;9:e113468
32. Umpierrez G, Atkin S, Bain S, et al. Efficacy and safety of liraglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomised trial. Diabetologia 2014;57:S84
33. Kaakeh Y, Kanjee S, Boone K, Sutton J. Liraglutide-induced acute kidney injury. Pharma-cotherapy 2012;32:e7-e11
34. U.S. Food and Drug Administration. Highlights of prescribing information. Available from http:// www.accessdata.fda.gov/drugsatfda-docs/label/ 2013/022341s020lbl.pdf. Accessed 26 January 2015
35. Astrup A, Rössner S, Van Gaal L, et al.; NN8022-1807 Study Group.Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-1616
36. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005;81:543-554
37. Yen TH, Lin JL, Lin-Tan DT, Hsu CW. Associ-ationbetween body mass and mortality inmain-tenance hemodialysis patients. Ther Apher Dial 2010;14:400-408
38. Kalantar-Zadeh K, Kopple JD. Obesity paradox in patients on maintenance dialysis. Contrib Nephrol 2006;151:57-69
39. Kalantar-Zadeh K, Streja E, Kovesdy CP, et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc 2010;85:991-1001
40. Idorn T, Knop FK, Jørgensen M, Holst JJ, Hornum M, Feldt-Rasmussen B. Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease. Kidney Int 2013;83:915-923
41. Idorn T, Knop FK, Jørgensen M, Holst JJ, Hornum M, Feldt-Rasmussen B. Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease. Nephrol Dial Transplant 2014;29:119-127